An open-label, two-part study to characterize the pharmacokinetics of a single intravenous dose of pazopanib (GW786034) and the absorption, distribution, metabolism and elimination of a single oral [14C] labeled dose of pazopanib in subjects with solid tumor malignancies.

Trial Profile

An open-label, two-part study to characterize the pharmacokinetics of a single intravenous dose of pazopanib (GW786034) and the absorption, distribution, metabolism and elimination of a single oral [14C] labeled dose of pazopanib in subjects with solid tumor malignancies.

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Mar 2012

At a glance

  • Drugs Pazopanib; Pazopanib
  • Indications Solid tumours
  • Focus Pharmacokinetics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 27 Oct 2008 Status changed from active, no longer recruiting to completed.
    • 05 Jun 2008 The expected completion date for this trial is now 1 Jul 2008 as reported by ClinicalTrials.gov.
    • 05 Jun 2008 Status changed from recruiting to in progress as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top